Results 61 to 70 of about 1,327 (186)
The Journal of Headache and PainBackground Rimegepant, a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, is indicated for acute and preventive migraine treatment in the United States and other countries.
Zhao Yang +13 more
doaj +1 more source
Cancer Neuroscience: Innovative Conception and Emerging Strategy of Therapy
MedComm, Volume 7, Issue 4, April 2026.In this review, we summarize nerve–cancer interactions and conclude two additional interactions, “perineural invasion” and “neuro‐microbic‐oncology.” Emphasizing the important role of nerves in tumor progression. The nervous system also contributes to the development of cancer comorbidities such as cancer depression and cognitive dysfunction.
Ting Wang +5 more
wiley +1 more source
Cost-effectiveness analysis of rimegepant for on-demand acute treatment of migraine in China
Frontiers in NeurologyPurposeThis study assesses the cost-effectiveness of rimegepant for the on-demand acute treatment of migraine in the Chinese population, focusing on headache relief within a 2 h timeframe.
Shuo Tian +6 more
doaj +1 more source
Meta-analysis and GRADE evidence profile of Rimegepant in the treatment of acute migraine
Sichuan jingshen weisheng, 2021 ObjectiveTo systematically evaluate the efficacy and safety of Rimegepant in the treatment of acute migraine.MethodsThe databases of CNKI， Wanfang and VIP database， PubMed， Embase， Cochrane Library， ClinicalTrials were searched to collect relevant ...
Liu Duo, Yan Yin
doaj +1 more source
The Journal of Qazvin University of Medical Sciences, 2022 Background The acute respiratory syndrome named “COVID-19” is caused by a novel coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Hanifeh Shariatifar +3 more
doaj +1 more source
Systematic review and meta-analysis on the efficacy and safety of rimegepant for migraine
Frontiers in NeurologyBackgroundMigraine is a prevalent neurological condition, affecting approximately 14% of the population, and is a leading cause of disability. Conventional treatments may have limited efficacy and tolerability limitations in clinical practice. Rimegepant
Tong An +6 more
doaj +1 more source
Gepants for Acute and Preventive Migraine Treatment: A Narrative Review
Brain Sciences, 2022 Calcitonin gene-related peptide (CGRP) antagonists are a class of medications that act as antagonists of the CGRP receptor or ligand. They can be divided into monoclonal antibodies and non-peptide small molecules, also known as gepants.
Jamir Pitton Rissardo +1 more
doaj +1 more source
Headache: The Journal of Head and Face Pain, Volume 66, Issue 4, Page 846-858, April 2026.Abstract Objectives/Background This study was undertaken to evaluate patient reasons for nonadoption of migraine‐preventive medications. Despite clear recommendations and eligibility criteria for migraine‐preventive treatment by the American Headache Society and the availability of these treatments, many people with migraine are not taking appropriate ...
Jessica Ailani +9 more
wiley +1 more source
Ubrogepant and rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies
Expert Opinion on Drug Safety, 2023 This study aimed at providing pooled estimates of the incidence of adverse drug reactions (ADRs) of ubrogepant and rimegepant and to use meta-regression to identify correlations between the occurrence of selected ADRs, socio-demographic, and clinical characteristics from data published in clinical studies.
Guojun Dong +3 more
openaire +3 more sources
Comparison of gepant effects at therapeutic plasma concentrations:connecting pharmacodynamics and pharmacokinetics [PDF]
Background: Orally administered second-generation gepants are effective for the treatment of migraine. The intranasal administration of the third-generation gepant zavegepant might have additional benefits including a rapid onset of action, but it is not
Boucherie, Deirdre M. +4 more
core +2 more sources